Ak, BilgesuGungor, OzgeKaraca, EminDurmaz, BurakBozer, Denis S.Tobu, MahmutAkin, Haluk2024-08-312024-08-3120242210-77622210-7770https://doi.org/10.1016/j.cancergen.2024.07.003https://hdl.handle.net/11454/104324The present study described an extremely rare case of acute promyelocytic leukemia (APL) characterized by a complex three-way (15;22;17)(q22;q11.2;q21) translocation. Acute promyelocytic leukemia (APL) is a specific subtype of acute myeloid leukemia with distinctive clinical and therapeutic characteristics. Besides being characterized by the t(15;17)(q22;q12) translocation, this subtype is also notable for its response to all-transretinoic acid (ATRA) treatment. APL is highly responsive to a combination of ATRA and chemotherapeutic agents, achieving over 90 % complete remission rates and over 80 % long-term remission rates. In this case, a 79- year-old male patient presented with complaints of weakness, fatigue, and petechial rash, with no other significant medical history except for diabetes mellitus and hypertension. Conventional cytogenetic methods, dual- color dual-fusion, and dual-color break-apart fluorescent in situ hybridization techniques together identified the t (15;22;17) translocation. RT-PCR analysis was performed for expression of PML/RARA fusion transcripts. The patient, diagnosed with APL, exhibited a complete response to all-trans retinoic acid (ATRA) and idarubicin treatment. In this paper, we present the second documented case of t(15;22;17) and explore the remarkable remission observed following treatment with All-Trans Retinoic Acid (ATRA).en10.1016/j.cancergen.2024.07.003info:eu-repo/semantics/closedAccessAplAcute Promyelocytic LeukemiaThree-Way TranslocationAtraArticle2864851WOS:0012904484000012-s2.0-8520034407439111247Q3N/A